Is Bloom Energy Flying Under the Radar?
Bloom Energy (NYSE:BE) manufactures scalable fuel cells for providing on-site…
Sell
29
NONOF Quote, Financials, Valuation and Earnings
Last price:
$64.58
Seasonality move
:
0.93%
Day range:
$62.93 - $66.41
52-week range:
$55.28 - $141.19
Dividend yield:
2.57%
P/E ratio:
19.12x
P/S ratio:
6.60x
P/B ratio:
14.28x
Volume:
827.5K
Avg. volume:
131.9K
1-year change:
-52.38%
Market cap:
$286.9B
Revenue:
$42.1B
EPS (TTM):
$3.38
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NONOF
Novo Nordisk AS
|
$11.9B | -- | 20.82% | -- | -- |
|
ASND
Ascendis Pharma AS
|
$167.5M | -$1.50 | 234.66% | -62.75% | $234.32 |
|
GLTO
Galecto
|
-- | -$2.82 | -- | -51.46% | $6.00 |
|
GMAB
Genmab AS
|
$900.9M | $0.34 | 17.19% | 7.82% | $30.50 |
|
LLY
Eli Lilly and
|
$14.5B | $5.55 | 34.58% | 472% | $952.27 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NONOF
Novo Nordisk AS
|
$64.58 | -- | $286.9B | 19.12x | $1.14 | 2.57% | 6.60x |
|
ASND
Ascendis Pharma AS
|
$169.90 | $234.32 | $10.3B | -- | $0.00 | 0% | 25.30x |
|
GLTO
Galecto
|
$3.59 | $6.00 | $4.7M | -- | $0.00 | 0% | -- |
|
GMAB
Genmab AS
|
$21.88 | $30.50 | $13.5B | 13.01x | $0.00 | 0% | 4.59x |
|
LLY
Eli Lilly and
|
$771.71 | $952.27 | $692.8B | 62.79x | $1.50 | 0.73% | 14.22x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NONOF
Novo Nordisk AS
|
46.15% | 1.580 | 5.63% | 0.54x |
|
ASND
Ascendis Pharma AS
|
128.87% | 0.160 | 9.75% | 0.67x |
|
GLTO
Galecto
|
-- | 2.596 | -- | -- |
|
GMAB
Genmab AS
|
-- | 0.135 | -- | 5.32x |
|
LLY
Eli Lilly and
|
70.96% | -0.134 | 5.19% | 0.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NONOF
Novo Nordisk AS
|
$9.2B | $5.5B | 53.78% | 84.88% | 54.06% | $1.4B |
|
ASND
Ascendis Pharma AS
|
$87.8M | -$106M | -59.13% | -880.05% | -48.32% | -$15.8M |
|
GLTO
Galecto
|
-- | -$2.6M | -- | -- | -- | -$2.4M |
|
GMAB
Genmab AS
|
$673M | $188M | 22.23% | 22.23% | 34.83% | $257M |
|
LLY
Eli Lilly and
|
$10.5B | $5.4B | 24.21% | 78.25% | 29.07% | -$1.6B |
Novo Nordisk AS vs. Competitors
-
Which has Higher Returns NONOF or ASND?
Ascendis Pharma AS has a net margin of 37.18% compared to Novo Nordisk AS's net margin of -93.73%. Novo Nordisk AS's return on equity of 84.88% beat Ascendis Pharma AS's return on equity of -880.05%.
Company Gross Margin Earnings Per Share Invested Capital NONOFNovo Nordisk AS83.49% $0.92 $37.3B ASNDAscendis Pharma AS82.65% -$1.66 $711.6M -
What do Analysts Say About NONOF or ASND?
Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 47.42%. On the other hand Ascendis Pharma AS has an analysts' consensus of $234.32 which suggests that it could grow by 37.92%. Given that Novo Nordisk AS has higher upside potential than Ascendis Pharma AS, analysts believe Novo Nordisk AS is more attractive than Ascendis Pharma AS.
Company Buy Ratings Hold Ratings Sell Ratings NONOFNovo Nordisk AS0 0 0 ASNDAscendis Pharma AS13 0 0 -
Is NONOF or ASND More Risky?
Novo Nordisk AS has a beta of 0.644, which suggesting that the stock is 35.566% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.376, suggesting its less volatile than the S&P 500 by 62.4%.
-
Which is a Better Dividend Stock NONOF or ASND?
Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.57%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NONOF or ASND?
Novo Nordisk AS quarterly revenues are $11B, which are larger than Ascendis Pharma AS quarterly revenues of $106.2M. Novo Nordisk AS's net income of $4.1B is higher than Ascendis Pharma AS's net income of -$99.6M. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.12x while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.60x versus 25.30x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NONOFNovo Nordisk AS6.60x 19.12x $11B $4.1B ASNDAscendis Pharma AS25.30x -- $106.2M -$99.6M
-
Which has Higher Returns NONOF or GLTO?
Galecto has a net margin of 37.18% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 84.88% beat Galecto's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NONOFNovo Nordisk AS83.49% $0.92 $37.3B GLTOGalecto-- -$1.92 -- -
What do Analysts Say About NONOF or GLTO?
Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 47.42%. On the other hand Galecto has an analysts' consensus of $6.00 which suggests that it could grow by 67.29%. Given that Galecto has higher upside potential than Novo Nordisk AS, analysts believe Galecto is more attractive than Novo Nordisk AS.
Company Buy Ratings Hold Ratings Sell Ratings NONOFNovo Nordisk AS0 0 0 GLTOGalecto0 1 0 -
Is NONOF or GLTO More Risky?
Novo Nordisk AS has a beta of 0.644, which suggesting that the stock is 35.566% less volatile than S&P 500. In comparison Galecto has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NONOF or GLTO?
Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.57%. Galecto offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Galecto pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NONOF or GLTO?
Novo Nordisk AS quarterly revenues are $11B, which are larger than Galecto quarterly revenues of --. Novo Nordisk AS's net income of $4.1B is higher than Galecto's net income of -$2.5M. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.12x while Galecto's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.60x versus -- for Galecto. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NONOFNovo Nordisk AS6.60x 19.12x $11B $4.1B GLTOGalecto-- -- -- -$2.5M
-
Which has Higher Returns NONOF or GMAB?
Genmab AS has a net margin of 37.18% compared to Novo Nordisk AS's net margin of 27.27%. Novo Nordisk AS's return on equity of 84.88% beat Genmab AS's return on equity of 22.23%.
Company Gross Margin Earnings Per Share Invested Capital NONOFNovo Nordisk AS83.49% $0.92 $37.3B GMABGenmab AS94.13% $0.31 $5.3B -
What do Analysts Say About NONOF or GMAB?
Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 47.42%. On the other hand Genmab AS has an analysts' consensus of $30.50 which suggests that it could grow by 39.4%. Given that Novo Nordisk AS has higher upside potential than Genmab AS, analysts believe Novo Nordisk AS is more attractive than Genmab AS.
Company Buy Ratings Hold Ratings Sell Ratings NONOFNovo Nordisk AS0 0 0 GMABGenmab AS4 3 0 -
Is NONOF or GMAB More Risky?
Novo Nordisk AS has a beta of 0.644, which suggesting that the stock is 35.566% less volatile than S&P 500. In comparison Genmab AS has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.249%.
-
Which is a Better Dividend Stock NONOF or GMAB?
Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.57%. Genmab AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Genmab AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NONOF or GMAB?
Novo Nordisk AS quarterly revenues are $11B, which are larger than Genmab AS quarterly revenues of $715M. Novo Nordisk AS's net income of $4.1B is higher than Genmab AS's net income of $195M. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.12x while Genmab AS's PE ratio is 13.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.60x versus 4.59x for Genmab AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NONOFNovo Nordisk AS6.60x 19.12x $11B $4.1B GMABGenmab AS4.59x 13.01x $715M $195M
-
Which has Higher Returns NONOF or LLY?
Eli Lilly and has a net margin of 37.18% compared to Novo Nordisk AS's net margin of 21.68%. Novo Nordisk AS's return on equity of 84.88% beat Eli Lilly and's return on equity of 78.25%.
Company Gross Margin Earnings Per Share Invested Capital NONOFNovo Nordisk AS83.49% $0.92 $37.3B LLYEli Lilly and82.53% $3.06 $54.4B -
What do Analysts Say About NONOF or LLY?
Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 47.42%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 23.4%. Given that Novo Nordisk AS has higher upside potential than Eli Lilly and, analysts believe Novo Nordisk AS is more attractive than Eli Lilly and.
Company Buy Ratings Hold Ratings Sell Ratings NONOFNovo Nordisk AS0 0 0 LLYEli Lilly and18 4 1 -
Is NONOF or LLY More Risky?
Novo Nordisk AS has a beta of 0.644, which suggesting that the stock is 35.566% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.
-
Which is a Better Dividend Stock NONOF or LLY?
Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.57%. Eli Lilly and offers a yield of 0.73% to investors and pays a quarterly dividend of $1.50 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NONOF or LLY?
Novo Nordisk AS quarterly revenues are $11B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Novo Nordisk AS's net income of $4.1B is higher than Eli Lilly and's net income of $2.8B. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.12x while Eli Lilly and's PE ratio is 62.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.60x versus 14.22x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NONOFNovo Nordisk AS6.60x 19.12x $11B $4.1B LLYEli Lilly and14.22x 62.79x $12.7B $2.8B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
61
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
55
TLN alert for Jul 19
Talen Energy [TLN] is up 24.44% over the past day.
Sell
48
CRSP alert for Jul 19
CRISPR Therapeutics AG [CRSP] is up 18.22% over the past day.
Buy
83
SOC alert for Jul 19
Sable Offshore [SOC] is up 11.86% over the past day.
